Sidley represented Jiangsu Hengrui Pharmaceuticals Co., Ltd. in connection with a license agreement with Novo Nordisk for HRS-1596, Hengrui Pharma’s phase 1-ready GLP-1/GIP dual receptor agonist designed for potential once-weekly oral dosing. Under the terms of the agreement, Novo will obtain exclusive rights to develop, manufacture, and commercialize HRS-1596 globally, excluding the Chinese mainland, the Hong Kong Special Administrative Region (SAR), the Macao SAR, and the Taiwan region. The potential total value of the agreement is up to US$2.6 billion contingent on the achievement of applicable development, regulatory, and commercial milestones. This includes a US$300 million upfront payment. In addition, Hengrui Pharma is eligible to receive royalties based on net sales of HRS-1596 within the licensed territory.
The Sidley team was led by Lila Hope, Jennifer Raab, and Jiqiang Lin (Technology and Life Sciences Transactions), and included Arif Noorani and Chen Yang (Food, Drug and Medical Device); Elizabeth Hardcastle and Taylor Andelman (Healthcare); Michael Alcan and Sophie Arkusinski (Tax); Miriam Carroll Silvestri (Antitrust and Competition); and Ash Nagdev and Stephanie Lim (Privacy and Cybersecurity).
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
